Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2010 May:21 Suppl 5:v165-7. doi: 10.1093/annonc/mdq201.

Authors

M Baccarani¹, M Dreyling; ESMO Guidelines Working Group

Affiliation

¹ Department of Hematology and Oncology 'L. and A. Seragnoli', University of Bologna, S. Orsola-Malpighi Hospital, Italy.

PMID: 20555071
DOI: 10.1093/annonc/mdq201

No abstract available

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Benzamides
Cytogenetic Analysis
Europe / epidemiology
Follow-Up Studies
Humans
Imatinib Mesylate
Immunotherapy
In Situ Hybridization, Fluorescence
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Leukocytosis / pathology
Neoplasm Staging
Piperazines / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use
Randomized Controlled Trials as Topic
Reverse Transcriptase Polymerase Chain Reaction
Risk Assessment
Thrombocytosis / pathology
Treatment Outcome

Substances

Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate